Importance of pre-analytical stability for CSF biomarker testing

Cerebrospinal Fluid in Clinical Neurology

Volumn , Issue , 2015, Pages 59-77

  Willemse, Eline A J ^a   Teunissen, Charlotte E ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944723989     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-01225-4_5     Document Type: Chapter

References (67)

1. Anesi A, Rondanelli M, D’Eril GM (1998) Stability of neuroactive amino acids in cerebrospinal fluid under various conditions of processing and storage. Clin Chem 44(11):2359-2360
2. Aziz N et al (1999) Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 6(1):89-95
3. Berven FS et al (2007) Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 1(7):699-711
4. Betsou F et al (2013) Identification of evidence-based biospecimen quality-control tools: a report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn 15(1):3—16
5. Bibl M et al (2004) Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 25(17):2912-2918
6. Bjerke M et al (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010:1-12
7. Bowen RAR et al (2005) Effect of blood collection tubes on total triiodothyronine and other laboratory assays. Clin Chem 51(2):424-433
8. Brandner S et al (2013) Neuroprotein dynamics in the cerebrospinal fluid: intraindividual concomitant ventricular and lumbar measurements. Eur Neurol 70(3-4):189-194
9. Bruegel M et al (2009) Standardized peptidome profiling of human cerebrospinal fluid by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Proteomics 72(4):608-615
10. Carrette O et al (2005) Truncated cystatin C in cerebrospinal fluid: technical [corrected] artefact or biological process? Proteomics 5(12):3060-3065
11. Chaigneau C et al (2007) Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 45(10):1390-1395
12. Deisenhammer F et al (2006) Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 13(9):913-922
13. Del Boccio P et al (2007) Cleavage of cystatin C is not associated with multiple sclerosis. Ann Neurol 62(2):201-204; discussion 205
14. del Campo M et al (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 6:419-430
15. Dobrowolska JA et al (2014) Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One 9(3):e89998
16. Downer EJ, Campbell VA (2010) Phytocannabinoids, CNS cells and development: a dead issue? Drug Alcohol Rev 29(1):91-98
17. Grant R et al (1991) Changes in intracranial CSF volume after lumbar puncture and their relationship to post-LP headache. J Neurol Neurosurg Psychiatry 54(5):440-442
18. Jimenez CR et al (2007) Endogenous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin Appl 1:1385-1392
19. Kaiser E et al (2007) Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 417(2):193-195
20. Kang J-E et al (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326(5955):1005-1007
21. Kang HJ et al (2013) Identification of clinical biomarkers for pre-analytical quality control of blood samples. Biopreserv Biobank 11(2):94-100
22. Klener J et al (2014) Instability of cerebrospinal fluid after delayed storage and repeated freezing: a holistic study by drop coating deposition Raman spectroscopy. Clin Chem Lab Med 52(5):657-664
23. Koel-Simmelink MJ et al (2014) The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 402(1-2):43-49
24. Kuntz KM et al (1992) Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology 42(10):1884-1887
25. Lehmann S et al (2014) Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. Alzheimers Dement 10(5):S390-S394.e2
26. Levine J et al (2000) Stability of CSF metabolites measured by proton NMR. J Neural Transm 107(7):843-848
27. Lewczuk P et al (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid p peptides. Clin Chem 52(2):332-334
28. Lomholt AF et al (2007) Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 380(1-2):128-132
29. Lu J, Grenache DG (2012) Development of a rapid, microplate-based kinetic assay for measuring adenosine deaminase activity in body fluids. Clin Chim Acta 413(19-20):1637-1640
30. Malekzadeh A et al (2012) Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 56(4):508-513
31. Mattsson N et al (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 9(3):251-261
32. Moghekar A et al (2012) Cerebrospinal fluid abeta and tau level fluctuation in an older clinical cohort. Arch Neurol 69(2):246-250
33. Muhle C et al (2013) Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. PLoS One 8(5):e62912
34. Murillo-Rodriguez E, Desarnaud F, Prospero-Garcia O (2006) Diurnal variation of arachidonoyle-thanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 79(1):30-37
35. Oliveira-da-Silva A et al (2009) Increased apoptosis and reduced neuronal and glial densities in the hippocampus due to nicotine and ethanol exposure in adolescent mice. Int J Dev Neurosci 27(6):539-548
36. Otto M et al (2012) Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 13(1):1-10
37. Perret-Liaudet A et al (2012) Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 31(1):13-20
38. Petzold A, Sharpe LT, Keir G (2006) Review spectrophotometry for cerebrospinal fluid pigment analysis. Neurocrit Care 0961:153-162
39. Pica-Mendez AM et al (2010) Nonspecific binding of Ap42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta 411(21-22):1833
40. Plebani M et al (2014) Harmonization of pre-analytical quality indicators. Biochem Med 24(1):105-113
41. Poulsen K et al (2012) Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 56(2):284-292
42. Ramont L et al (2005) Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med 43(11):1215-1217
43. Reiber H (2003) Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 21(3-4):79-96
44. Rosenling T et al (2011) The impact of delayed storage on the measured proteome and metabo-lome of human cerebrospinal fluid. Clin Chem 57(12):1703-1711
45. Salvesen L et al (2014) The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid. Biomark Med 8(3):387-394
46. Schipke CG et al (2011) Long-term stability of Alzheimer’s disease biomarker proteins in cerebrospinal fluid. J Alzheimers Dis 26(2):255-262
47. Schoonenboom NSM et al (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51(1):189-195
48. Simonsen AH et al (2010) Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J Neurosci Methods 191(2):244-248
49. Simonsen AH et al (2013) Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 215(2):234-240
50. Sulik A, Wojtkowska M, Oldak E (2008) Preanalytical factors affecting the stability of matrix metalloproteinase-2 concentrations in cerebrospinal fluid. Clin Chim Acta 392(1-2):73-75
51. Sunderland T et al (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16):2094-2103
52. Tarnaris A et al (2011) Rostrocaudal dynamics of CSF biomarkers. Neurochem Res 36(3):528-532
53. Teunissen CE et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914-1922
54. Teunissen CE et al (2010) Standardization of assay procedures for analysis of the CSF biomarkers amyloid P(1-42), tau, and phosphorylated tau in Alzheimer’s disease: report of an International workshop. Int J Alzheimers Disease Volume 2010, pp 1-6. doi:10.4061/2010/635053
55. Teunissen C et al (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 19:1802-1809
56. Teunissen CE et al (2014) Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem 47(4-5):288-292
57. Toombs J et al (2014) Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther 6(1):5
58. Triendl A (2000) Die klinische Wertigkeit des monoklonalen und biklonalen Bandenmusters in der isoelektrischen Fokussierung des Liquor cerebrospinalis. Univ., Diss, Innsbruck
59. Tumani H, Brettschneider J (2005) Brain specific proteins in cerebrospinal fluid (CSF): factors influencing their concentration in CSF and clinical relevance. Laboratoriumsmedizin 29(6):421-428
60. Turner HE et al (2013) The effect of electronic ordering on pre-analytical errors in primary care. Ann Clin Biochem 50(Pt 5):485-488
61. Vanderstichele H et al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement 8(1):65-73
62. Verwey NA et al (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46(Pt 3):235-240
63. Vos SJB et al (2014) Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS One 9(6):e100784
64. Yang J et al (2011) Stability analysis of vascular endothelial growth factor in cerebrospinal fluid. Neurochem Res 36(11):1947-1954
65. You J-S et al (2005) The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5:290-296
66. Zander J et al (2014) Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma. Clin Chem Lab Med 52(5):629-639
67. Zimmermann R et al (2011) Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 25(4):739-745